Form D · Pharmaceuticals

Novira Therapeutics, Inc.

Doylestown, PA · CIK 0001556754

Offering snapshot reported Dec 24, 2014 · SEC filing

Reported sold
$9M
Offering amount: $9M
Investors reported
10
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 12, 2014
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 24, 2014Initial$9,000,000No comparison10SEC filing
Feb 11, 2014Amendment$27,995,233$17,000,012vs Aug 23, 201210SEC filing
Aug 23, 2012Initial$10,995,221No comparison8SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-230841
Does not include purchase price in the aggregate amount of $90.00 paid for warrants issued in transaction.

Source: Form D, filed Dec 24, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Nathaniel Brown Executive
Douglas Carr Executive
Osvaldo Flores Executive
Anthony Ford Hutchinson Director
Daniel E. Geffken Executive
Gianni Gromo Director
George Hartman Executive
Klaus Klumpp Executive
Gregory Korbel Executive
Scott M. Rocklage Director
Christian S. Schade Director, Executive
Tim Shannon Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
3805 Old Easton Road
Doylestown, PA, 18902